The wound covering VersaShield, which is processed from placental tissue by The Musculoskeletal Transplant Foundation (MTF), is an amniotic allograft tissue recovered from living donors during healthy child births.

Musculoskeletal Transplant Foundation CEO Bruce Stroever said for more than a century, doctors have used amniotic tissue for various clinical applications in general surgery, dental, Ob/Gyn, ocular surgery, spine and sports medicine.

"This is due to the beneficial anti-inflammatory, anti-adhesive, anti-microbial, and non-immunogenic properties of the tissue graft," Stroever added.

"MTF is pleased to continue our partnership with Orthofix on the introduction of VersaShield amniotic membrane in order to make innovative biologic solutions available to all spine and orthopedic surgeons."

Orthofix president and chief executive officer Robert Vaters said the company is excited to display its second biologic tissue form from MTF this week at the 2012 North American Spine Society meeting.

"This launch further demonstrates our commitment to expand our biologic offering, which goes hand in hand with our Value Proposition of providing surgeons a breadth of hardware, biologic, and stimulation solutions," Vaters added.